How big is the U.S. respiratory syncytial virus vaccines market?

The global market is set to reach US$ 604.8 Mn in 2025.

What is the projected growth rate of the U.S. respiratory syncytial virus vaccines market?

The market is projected to record a CAGR of 15.6% during the forecast period from 2025 to 2032.

What drives the U.S. respiratory syncytial virus vaccines market?

Increasing awareness of RSV’s impact on vulnerable populations, growing vaccine adoption, and advancements in vaccine technology for both adults and infants is expected to drive the global market.

What is the leading segment for distribution channel?

Institutional sales is the leading segment for distribution channel.

Who are the key players in the U.S. respiratory syncytial virus vaccines market?

Pfizer Inc., Sanofi, Merck Sharp & Dohme, and GlaxoSmithKline are some leading players.

Table of Content - U.S. Respiratory Syncytial Virus Vaccines Market Size, Share, Trends, Growth, and Forecast, 2025

Executive Summary
1. U.S. Respiratory Syncytial Virus Vaccines Market Snapshot, 2025 and 2032
2. Market Opportunity Assessment, 2025 - 2032, US$ Mn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Industry Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Key Trends
3. Macro-Economic Factors
  1. U.S. Sectorial Outlook
  2. U.S. GDP Growth Outlook
4. COVID-19 Impact Analysis
5. Forecast Factors - Relevance and Impact
Value Added Insights
1. Product Adoption Analysis
2. Disease Epidemiology
3. Regulatory Landscape
4. Porter’s Five Forces Analysis
5. PESTLE Analysis
6. Promotional Strategies, By Key Players
U.S. Respiratory Syncytial Virus Vaccines Market Outlook
1. Key Highlights
  1. Market Size (US$ Mn) and Y-o-Y Growth
  2. Absolute $ Opportunity
2. Market Size (US$ Mn) Analysis and Forecast
  1. Historical Market Size (US$ Mn) Analysis, 2019 - 2024
  2. Market Size (US$ Mn) Analysis and Forecast, 2025 - 2032
3. U.S. Respiratory Syncytial Virus Vaccines Market Outlook: Drug
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Drug, 2019 - 2024
  3. Market Size (US$ Mn) Analysis and Forecast, By Drug, 2025 - 2032
    1. Palivizumab
    2. ABRYSVO (RSVpreF PF06928316)
    3. Arexvy - RSVPreF3 OA (GSK3844766A)
    4. mRESVIA (mRNA-1345)
    5. Janssen RSV Vaccine
    6. ResVax
    7. Nirsevimab (MEDI8897)
    8. MVA-BN RSV
  4. Market Attractiveness Analysis: Drug
4. U.S. Respiratory Syncytial Virus Vaccines Market Outlook: Distribution Channel
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn), By Distribution Channel, 2019 - 2024
  3. Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    1. Institutional Sales
      1. Hospitals
      2. Specialty Clinics
      3. Academic and Research Institutes
    2. Retail Sales
      1. Retail Pharmacy
      2. Drug Stores
    3. Online Sales
  4. Market Attractiveness Analysis: Distribution Channel
Competition Landscape
1. Market Share Analysis, 2024
2. Market Structure
  1. Competition Intensity Mapping By Market
  2. Competition Dashboard
3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  1. Pfizer Inc.
    1. Overview
    2. Segments and Products
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. Sanofi
  3. Merck Sharp & Dohme
  4. GlaxoSmithKline
  5. SOBI
  6. Johnson & Johnson
  7. Bavarian Nordic
  8. Novavax
  9. AstraZeneca
  10. Moderna, Inc.
  11. Codagenix Inc.
  12. Intravacc BV.
  13. Alphavax, Inc.
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

U.S. Respiratory Syncytial Virus Vaccines Market Size, Share, Trends, Growth, and Forecast, 2025 - 2032

U.S. Respiratory Syncytial Virus Vaccines Market by Drug (Palivizumab, ABRYSVO (RSVpreF PF06928316), Arexvy, RSVPreF3 OA (GSK3844766A), mRESVIA (mRNA-1345), Janssen RSV Vaccine, ResVax, Nirsevimab (MEDI8897), MVA-BN RSV), by Distribution Channel Analysis for 2025 - 2032

Quick Links

Our Partners

Secure Payments Through